Imexpharm

Imexpharm FCF Yield

The Free Cash Flow Yield of Imexpharm (IMP.VN) as of Oct 26, 2026 is 0.33 %. In the previous year, Free Cash Flow Yield was 1.45 % — a change of -77.16% (lower).

FCF Yield

0.33 %

YoY

-77.16%

Last updated:

Free Cash Flow Yield of Imexpharm is 2025 0.33 % . Free Cash Flow Yield of Imexpharm was 2024 1.45 % . It decreases by -77.16% lower compared to the previous year.

The Imexpharm FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-1.71 VND
Jan 1, 2019
-0.78 VND
Jan 1, 2020
-0.20 VND
Jan 1, 2021
2.21 VND
Jan 1, 2022
3.40 VND
Jan 1, 2023
-1.26 VND
Jan 1, 2024
1.45 VND
Jan 1, 2025
0.33 VND
The Imexpharm FCF Yield history
YEARFCF YieldYoY
0.33 %-77.16%
1.45 %-215.38%
-1.26 %-137.09%
3.40 %+53.41%
2.21 %-1,201.09%
-0.20 %-74.38%
-0.78 %-54.02%
-1.71 %-20.82%
-2.16 %+820.58%
-0.23 %-37.06%
-0.37 %+93.10%
-0.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

Free Cash Flow Yield of Imexpharm is 0.33 % in 2025.

Free Cash Flow Yield of Imexpharm changed from 1.45 % to 0.33 %, representing a -77.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Imexpharm since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Imexpharm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Imexpharm

All Key Metrics — Imexpharm